SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is currently experiencing intense retail-driven volatility and a massive short squeeze, fueled by an extremely low float and sky-high borrow fees. The community is sharply divided, with bulls betting on further parabolic gains to triple digits while skeptics warn of an imminent rug pull and long-term dilution risks.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit Inc. is trending following a massive quarterly earnings beat that surpassed revenue and EPS expectations, fueling community debate over the company's long-term ad monetization and AI data licensing potential. While some investors remain cautious of potential post-earnings volatility, many are focused on the stock's growth trajectory and whether it will maintain its momentum for S&P 500 inclusion.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending following a record-breaking fiscal quarter where a double beat on revenue and earnings, coupled with a massive new share buyback authorization, has fueled bullish sentiment among investors. The community is focused on the company's strong geographic growth and dividend increase, with many debating the impact of the upcoming CEO transition and future AI product integration.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is facing heightened volatility ahead of earnings as investors debate its long-term cash burn against operational milestones like the start of R2 production. Community discourse is sharply divided between bulls focused on the R2's potential to scale production and skeptics who are concerned about executive compensation packages and the company's ongoing capital requirements.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is facing intense selling pressure and a sharp decline following disappointing engagement metrics and a downward revision to its bookings guidance. The community is deeply polarized, with some investors viewing the dip as an opportunistic long-term entry, while critics are pointing to ongoing concerns regarding user safety, management's profitability struggles, and the potential for further structural growth stagnation.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is seeing significant trading activity driven by news of a milestone payment from Boehringer Ingelheim and anticipation surrounding their upcoming clinical milestones. The community is actively debating the company's long-term pivot toward autoimmune therapies under new leadership, while traders weigh the impact of potential financial restructuring against the stock's recent volatility.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as community members rally behind a mission to rebuild the project's reputation and value, emphasizing long-term resilience over short-term hype. Despite past volatility and team turnover, holders are actively discussing the importance of organic growth and educational initiatives while viewing current price levels as a significant accumulation opportunity.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian is experiencing a major surge following a strong earnings report that beat expectations on both revenue and earnings, signaling potential stabilization for the broader SaaS sector. While the community remains divided over the long-term impact of AI on software demand, investors are actively discussing whether this momentum marks a sustainable recovery for beaten-down growth stocks or a temporary relief rally.

AIOS Tech, Inc. is an investment holding company, which engages in the provision of financing solutions to small- and mid-size enterprises. The company was founded on May 29, 2012 and is headquartered in Shanghai, China.

AIOS Tech Inc. - Ordinary Shares - Class A

AIOS Tech Inc.

AIOS Tech is seeing high-volatility momentum as traders monitor a low-float setup following a recent reverse stock split. Community discussion remains polarized, with some tracking the stock for potential squeeze opportunities while others express caution regarding ongoing dilution concerns and long-term liquidity.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is trending following a massive earnings beat and strong forward guidance that highlighted robust data center demand. While investors are debating the sustainability of this valuation after a significant year-long rally, the community is actively discussing the impact of a newly authorized share buyback program as a defensive measure against short selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Inhibrx Biosciences Highlights 20% ORR for Ozekibart Combo in Late-Line Colorectal Cancer

Inhibrx Biosciences (NASDAQ:INBX) shared a clinical update on ozekibart in advanced colorectal cancer, highlighting Phase I/II data evaluating ozekibart in combination with FOLFIRI in a heavily...

Inhibrx Biosciences (NASDAQ:INBX) Upgraded at Lifesci Capital

Lifesci Capital raised shares of Inhibrx Biosciences to a "strong-buy" rating in a research report on Friday...

Inhibrx Biosciences (NASDAQ:INBX) Trading Up 9.4%  - Should You Buy?

Inhibrx Biosciences (NASDAQ:INBX) Trading Up 9.4% - Still a Buy...

INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study

Inhibrx Biosciences stock surges after phase I/II CRC data of ozekibart show strong response rates and durable benefit, alongside a new FDA filing for ozekibart in chondrosarcoma.

Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges

Inhibrx explores spin-off of INBRX-106 amid Big Pharma interest, with potential valuation exceeding $9 billion pending trial outcomes.read more...

Inhibrx Biosciences (NASDAQ:INBX) Sets New 52-Week High  - Here's What Happened

Inhibrx Biosciences (NASDAQ:INBX) Sets New 1-Year High - Time to Buy...

<ul><li>The therapy, which is being tested alone and in combination with Keytruda, a prescription immunotherapy, could be valued at over $8 billion, according to the report.</li><li>Inhibrx Biosciences could also spin off INBRX-106, along with another experimental cancer drug, into a separate entity.</li><li>The biotech firm reported promising interim data from its Phase 1/2 trial for advanced colorectal cancer on Tuesday.</li></ul>Shares of Inhibrx Biosciences (INBX) surged more than 40% on Wednesday to an all-time high, following reports of potential deal interest in its cancer pipeline, adding to momentum from encouraging early-stage colorectal cancer trial results.<h2>All Eyes On INBRX-106</h2>According to a Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/world/merck-rivals-eye-deal-inhibrx-experimental-cancer-drug-tied-keytruda-sources-say-2026-04-22/">report</a> on Wednesday,&nbsp;Inhibrx Biosciences has attracted early-stage interest from major drugmakers including Merck &amp; Co. (MRK), and Ono Pharmaceutical, for its experimental drug INBRX-106.The therapy, which is being tested alone and in combination with Keytruda, a prescription immunotherapy, could be valued at over $8 billion if trials confirm its potential to boost treatment response rates.The biotech firm could also spin off INBRX-106, along with another experimental cancer drug, into a separate entity that could be worth over $9 billion if trials are successful.<h2>New Cancer Drug Shows Promise</h2>Meanwhile, its second key asset, Ozekibart, is also gaining traction after Inhibrx Biosciences reported interim Phase 1/2 data for advanced colorectal cancer, showing promising results in pretreated patients.Among 45 patients, the treatment achieved a 20% response rate, well above the typical 1% - 6% seen with standard therapies. Nearly half of these responses lasted more than six months. The median progression-free survival was 5.5 months, and 42% of patients remained progression-free at 6 months.The therapy also showed a manageable safety profile, with mostly mild to moderate side effects such as diarrhea, fatigue, and nausea. Inhibrx plans to meet with the U.S. Food and Drug Administration (FDA) later this year to discuss advancing the treatment into late-stage trials.<h2>INBX Stock: How Did Retail Traders React?</h2>Retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/INBX">INBX</a> turned ‘extremely bullish’ from ‘bullish’ a day earlier, amid ‘high’ message volumes.One user noted “very strong data” from the Ozekibart trial.<stembedurl>https://stocktwits.com/BullStockpicks1/message/650960093</stembedurl>Another user was bullish about the firm’s prospects.<stembedurl>https://stocktwits.com/Terzman/message/650834526</stembedurl>Year-to-date, the stock has gained around 5%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising chart and reflection of business buildings: stock photo courtesy of Yuichiro Chino via Getty Images

INBX Stock Hit Record Highs: Cancer Therapies Reportedly Draw Big Pharma Interest

Inhibrx Biosciences has attracted early-stage interest from major drugmakers including Merck & Co. and Ono Pharmaceutical, for its experimental drug INBRX-106, according to a Reuters report.

INBX Stock Hit Record Highs: Retail Turns ‘Extremely Bullish’ On This Cancer Play 

Equity

Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer PR Newswire SAN...

Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer

Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart...

Inhibrx Biosciences (NASDAQ:INBX) Shares Down 5.2% - What's Next?

Inhibrx Biosciences (NASDAQ:INBX) Stock Price Down 5.2% - Should You Sell...

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

INBX
Inhibrx Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest INBX News

INBXInhibrx Inc